Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Johnson_&_Johnson
|
| gptkbp:acquisitionYear |
1961
|
| gptkbp:foundedBy |
gptkb:Paul_Janssen
|
| gptkbp:foundedYear |
1953
|
| gptkbp:headquartersLocation |
gptkb:Beerse,_Belgium
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:notableProduct |
gptkb:Edurant
gptkb:Prezista gptkb:Reminyl gptkb:Risperdal gptkb:Stelara gptkb:Imodium Fentanyl |
| gptkbp:numberOfEmployees |
over 5000
|
| gptkbp:parentCompany |
gptkb:Johnson_&_Johnson
|
| gptkbp:products |
Pharmaceutical drugs
|
| gptkbp:researchInterest |
Neuroscience
Oncology Immunology Infectious diseases Cardiovascular and metabolic diseases |
| gptkbp:website |
https://www.janssen.com/
|
| gptkbp:bfsParent |
gptkb:Janssen_Pharmaceutica
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Janssen Pharmaceutica N.V.
|